Combination immunotherapy for advanced lung cancer.
Therapeutic strategies using cytokines have not been extensively tested in patients with advanced non-small-cell lung cancer (NSCLC). We developed a basic laboratory and clinical research program to investigate the effective immunotherapeutic manipulations for activating the endogenous immune system with biological agents. Our efforts using low-dose interleukin 2 in conjunction with other biologic response modifiers for the treatment of NSCLC are summarized here.
Yang
S C
SC
Department of General Surgery, University of Texas Health Science Center, Houston.
Grimm
E A
EA
Roth
J A
JA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000628:therapy*; D016853:Muromonab-CD3 / Q000008:administration & dosage*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
D007376:Interleukin-2; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha